Neoadjuvant NAUTIKA1 Data, Broad Molecular Profiling, and Clinical Pearls

The faculty discuss the NAUTIKA1 data on neoadjuvant divarasib in resectable KRAS G12C-mutated NSCLC, including the small numbers behind the down staging results and why this makesunderstanding the biomarker status of patients as soon as possible so important. They then discuss broad molecular profiling from the day of diagnosis, with tissue and plasma used together or in sequence, and the shared responsibility of oncologists, pathologists, interventional pulmonologists, and surgeons. Closing pearls cover repeating molecular testing at progression to understand acquired resistance and open the door to clinical trials, testing broadly at diagnosis because a limited panel is not enough, and not relying on a ‘negative’ liquid biopsy alone.